Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

For patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) admitted to the intensive care unit ...

GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.

Medically reviewed by Susan Russell, MD Key Takeaways Obstructive lung diseases like COPD cause trouble when you're exhaling air.Restrictive lung diseases like pulmonary fibrosis make it harder to ...

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterised by persistent airflow limitation and chronic inflammation. Beyond its primary pulmonary manifestations, ...

GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...

Shortness of breath when walking short distances can occur suddenly or be a chronic condition. It should be evaluated, as it ...

Quit smoking and control your indoor air quality. Exposure to smoke, dust, fumes, vapors and chemicals can worsen your COPD.

Deaths from infectious diseases fall, while chronic conditions like diabetes, Alzheimer’s and drug use disorders increase globally - Anadolu Ajansı ...

The 3TR project aims to transform the understanding and treatment of immune-mediated diseases, with its core principles in ...